🇺🇸 FDA
Patent

US 11753627

Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4

granted A61KA61K2039/5254A61K2039/5256

Quick answer

US patent 11753627 (Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Sep 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
4
CPC classes
A61K, A61K2039/5254, A61K2039/5256, A61K2039/70, A61K39/12